Japan Approves Remdesivir For Use On Severe COVID-19 Patients

Japan approved the antiviral drug Remdesivir of the Gilead Sciences for the treatment of severe COVID-19 patients, making itself and the United States are the only two countries who have authorized use of remdesivir for the treatment of COVID-19.

The approval is under an exceptional approval pathway based on clinical data of phase III trial from the U.S. National Institute of Allergy and Infectious Diseases, referencing the United States’ Emergency Use Authorization of the drug to treat severe cases of COVID-19.

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

PharmaSources.com is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.